Find Clinical Trial

Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of the daily dose from 150 to 300 mg per day per os). A 2-year randomised, parallel group, placebo controlled study in IPD “de novo” patients.

← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationParkinson's disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS004200
Protocol CodeCL3-04200-006

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.